Dislipidemia relacionada à fibrose cística

Alves, Crésio; Lima, Daniela C. A.

doi:10.1590/s1806-37132008001000012

Cited by 5 publications

(58 citation statements)

References 33 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[620] In the present report, hypercholesterolemia was found in 17.4% of the patients (of whom 38% did not present pancreatic insufficiency). Of the patients without pancreatic insufficiency, only three presented hypercholesterolemia (with TC levels ranging between 171 and 179 mg/dL).…”

Section: Discussionsupporting

confidence: 54%

“…[56] The mechanisms postulated to explain this disturbance are: diet rich in carbohydrates and poor in fats, diabetes, liver disease, elevation of pro-inflammatory cytokines and use of corticosteroids, probably all acting in a combined manner. [5–7] Recently, lung transplantation was described as being associated with hyperlipidemia in CF patients, probably related to cyclosporine use.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dyslipidemia in racially admixtured children with cystic fibrosis

Alves

Lima

Cardeal

et al. 2012

Indian J Endocr Metab

View full text Add to dashboard Buy / Rent full text

Objectives:There are few studies reporting lipid profile in cystic fibrosis (CF) and most of them are in adult Caucasians. Therefore, the aim of this study was to evaluate the lipid profile of racially admixtured youths with CF.Materials and Methods:A cross-sectional survey conducted between August and September 2009 at a reference service for CF, evaluating clinical and laboratory data.Results:Forty-six patients aged from 6 years to 16 years and 2 months (median: 9 years and 10 months; 65.2% males) were evaluated. Of these, 26% were Whites, 54.4% Mulattoes and 19.6% Blacks. There were no diabetics, one patient had glucose intolerance and three had insulin resistance. Pancreatic sufficiency was present in 74% and malnutrition in 26% of the patients. The lipid profile revealed hypertriglyceridemia in 56%, hypercholesterolemia in 17.4% and hypocholesterolemia in 46.5%. In 30.4% of the patients, hypertriglyceridemia and hypocholesterolemia was observed. The serum levels of high density lipoprotein (HDL) were low in 56.5% and the low density lipoprotein (LDL) elevated in 15.2% of the patients.Conclusions:The lipid profile of this sample of Brazilian racially admixtured patients with CF showed a higher prevalence of hypertriglyceridemia and hypocholesterolemia. There was no association of dyslipidemia with the various racial groups, nutritional status, pancreatic sufficiency or glucose tolerance.

show abstract

Section: Discussionsupporting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Dyslipidemia in racially admixtured children with cystic fibrosis

Alves

Lima

Cardeal

et al. 2012

Indian J Endocr Metab

View full text Add to dashboard Buy / Rent full text

show abstract

“…In 2003 a diagnosis of CF was made by studying the mutations of the gene encoding the CFTR protein, which functions as a chloride channel within a number of epithelial tissues, typically involved in this disease. He showed a CFTR exocrine pancreatic insufficiency and fat malabsorption, as in 90% of adult CF patient,6 and a CF-related diabetes (40% of adults)7 treated with insulin. As CF-related bone disease he presented osteoporosis, common in adult CF patients,8 treated with calcium and biphosphonates.…”

mentioning

confidence: 99%

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

Gentilini

Levi

Federico

et al. 2012

Mediterr J Hematol Infect Dis

View full text Add to dashboard Buy / Rent full text

Introduction:Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).Methods:We used Bortezomib without corticosteroids, to avoid the risk of lung infection reactivations due to patient’s Pseudomonas aeruginosa colonization, in a MM patient with Cystic Fibrosis. Four 21-day cycles of Bortezomib were administrated at 1.3 mg/m2 on days 1,4,8 and 11 with a 10 day rest period. Treatment response and toxicity were evaluated.Results:After four cycles of therapy the patient achieved a very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.Conclusions:Bortezomib can be successfully utilized for the management of this difficult disease situation.

show abstract

Dislipidemia relacionada à fibrose cística

Cited by 5 publications

References 33 publications

Dyslipidemia in racially admixtured children with cystic fibrosis

Dyslipidemia in racially admixtured children with cystic fibrosis

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

Contact Info

Product

Resources

About